Current developments in intraspinal agents for cancer and noncancer pain

Current Pain and Headache Reports

Volumn 14, Issue 1, 2010, Pages 8-16

  Lawson, Erin F ^a   Wallace, Mark S ^a  

^a University of California   (United States)

Author keywords

Intrathecal drug delivery; Ziconotide

Indexed keywords

ADENOSINE; ANALGESIC AGENT; ANALGESIC, ANTIINFLAMMATORY, ANTIRHEUMATIC AND ANTIGOUT AGENTS; BUPIVACAINE; BUPRENORPHINE; CGX 1160; CLONIDINE; FENTANYL; GABAPENTIN; HYDROMORPHONE; KETOROLAC; MIDAZOLAM; MORPHINE; NEOSTIGMINE; OCTREOTIDE; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN MVIIA; P SAPORIN; PETHIDINE; PLACEBO; RESINIFERATOXIN; ROPIVACAINE; SAPORIN; SUFENTANIL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; XEN 2174;

ABSENCE OF SIDE EFFECTS; ALLODYNIA; ATAXIA; BLOOD BRAIN BARRIER; BRADYCARDIA; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; EMOTIONAL DISORDER; EPILEPSY; GAIT DISORDER; HEADACHE; HUMAN; HYPERALGESIA; HYPOTENSION; INFUSION PUMP; INTRACTABLE PAIN; LOW DRUG DOSE; MEMORY DISORDER; MOTOR DYSFUNCTION; NAUSEA; NEOPLASM; NERVOUSNESS; NEUROPATHIC PAIN; NONHUMAN; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; PAIN; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; REVIEW; SEDATION; SENSORY DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINE RETENTION;

ALGORITHMS; ANALGESICS; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, SPINAL; NEOPLASMS; PAIN;

EID: 77649186185     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-009-0092-z     Document Type: Review

References (66)

1. Smith HS, Deer TR, Staats PS, et al.: Intrathecal drug delivery. Pain Physician 2008, 11 (2 Suppl):S89-S104.
2. Deer T, Krames ES, Hassenbusch SJ, et al.: Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2007, 10:300-328. This is the most recent consensus guidelines, a result of a consensus meeting of top experts on spinal drug delivery.
3. Bennett G, Burchiel K, Buchser E, et al.: Clinical guidelines for intraspinal infusion: report of an expert panel. PolyAnalgesic Consensus Conference 2000. J Pain Symptom Manage 2000, 20: S37-S43.
4. Hassenbusch SJ, Portenoy RK, Cousins M, et al.: Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-report of an expert panel. J Pain Symptom Manage 2004, 27:540-563.
5. Bennett G, Deer T, Du Pen S, et al.: Future directions in the management of pain by intraspinal drug delivery. J Pain Symptom Manage 2000, 20:S44-S50.
6. Pirec V, Laurito CE, Lu Y, Yeomans DC: The combined effects of N-type calcium channel blockers and morphine on A delta versus C fiber mediated nociception. Anesth Analg 2001, 92:239-243.
7. Rauck RL, Wallace MS, Leong MS, et al.: A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006, 31:393-406.
8. Staats PS, Yearwood T, Charapata SG, et al.: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004, 291:63-70.
9. Wallace MS, Rauck R, Fisher R, et al.: Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth Analg 2008, 106:628-637, table of contents.
10. Wallace MS, Fisher R, Byas-Smith M, et al.: Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo controlled clinical trial. Neuromodulation 2006, 9:75-86.
11. Wallace MS, Kosek PS, Staats P, et al.: Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med 2008, 9:271-281.
12. Webster LR, Fakata KL, Charapata S, et al.: Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med 2008, 9:282-290.
13. Ilias W, Todoroff B: Optimizing pain control through the use of implantable pumps. Med Dev Evid Res 2008, 1:41-47.
14. Webster LR, Fisher R, Charapata S, Wallace MS: Long-term intrathecal ziconotide for chronic pain: an open-label study. J Pain Symptom Manage 2009, 37:363-372.
15. Prialt (ziconotide intrathecal infusion) package insert: Manufactured by Elan Pharmaceuticals, Dublin, Ireland.
16. Bouchenafa O, Livingston A: Autoradiographic localisation of alpha 2 adrenoceptor binding sites in the spinal cord of the sheep. Res Vet Sci 1987, 42:382-386.
17. Eisenach JC, DuPen S, Dubois M, et al.: Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain 1995, 61:391-399.
18. Berde CB, Sethna NF, Conrad LS, et al.: Subarachnoid bupivacaine analgesia for seven months for a patient with a spinal cord tumor. Anesthesiology 1990, 72:1094-1096.
19. Lau WC, Green CR, Faerber GJ, et al.: Determination of the effective therapeutic dose of intrathecal sufentanil for extracorporeal shock wave lithotripsy. Anesth Analg 1999, 89:889-892.
20. Nitescu P, Dahm P, Appelgren L, Curelaru I: Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of "refractory" nonmalignant pain. Clin J Pain 1998, 14:17-28. (Pubitemid 28146045)
21. Budd K: High dose buprenorphine for postoperative analgesia. Anaesthesia 1981, 36:900-903.
22. Canavero S, Bonicalzi V, Clemente M: No neurotoxicity from long-term (>5 years) intrathecal infusion of midazolam in humans. J Pain Symptom Manage 2006, 32:1-3.
23. Yaksh TL, Allen JW: The use of intrathecal midazolam in humans: a case study of process. Anesth Analg 2006, 98:1536-1545.
24. Kroin JS, Ling ZD, Buvanendran A, Tuman KJ: Upregulation of spinal cyclooxygenase-2 in rats after surgical incision. Anesthesiology 2004, 100:364-369.
25. Eisenach JC, Curry R, Hood DD, Yaksh TL: Phase I safety assessment of intrathecal ketorolac. Pain 2002, 99:599-604.
26. Yaksh TL, Horais KA, Tozier N, et al.: Intrathecal ketorolac in dogs and rats. Toxicol Sci 2004, 80:322-334.
27. Chaudhari LS, Kane DG, Shivkumar B, Kamath SK: omparative study of intrathecal pethidine versus lignocaine as an anaesthetic and a postoperative analgesic for perianal surgery. J Postgrad Med 1996, 42:43-45.
28. Coderre TJ, Kumar N, Lefebvre CD, Yu JS: Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005, 94:1131-1139.
29. Cheng JK, Chen CC, Yang JR, Chiou LC: The antiallodynic action target of intrathecal gabapentin: Ca2+ channels, KATP channels or N-methyl-d-aspartic acid receptors? Anesth Analg 2006, 102:182-187.
30. Luer MS, Hamani C, Dujovny M, et al.: Saturable transport of gabapentin at the blood-brain barrier. Neurol Res 1999, 21:559-562.
31. Deer T, Kim CK, Bowman RG, et al.: The use of continuous intrathecal infusion of octreotide in patients with chronic pain of noncancer origin: an evaluation of side-effects and toxicity in a prospective double-blind fashion. Neuromodulation 2005, 8:171-175.
32. Tsai YC, So EC, Chen HH, et al.: Effect of intrathecal octreotide on thermal hyperalgesia and evoked spinal c-Fos expression in rats with sciatic constriction injury. Pain 2002, 99:407-413.
33. Paice JA, Penn RD, Shott S: Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage 1996, 11:71-80.
34. Yoon MH, Bae HB, Choi JI, et al.: Roles of adenosine receptor subtypes in the antinociceptive effect of intrathecal adenosine in a rat formalin test. Pharmacology 2006, 78:21-26.
35. Eisenach JC, Hood DD, Curry R, et al.: Intrathecal but not intravenous opioids release adenosine from the spinal cord. J Pain 2004, 5:64-68.
36. Li X, Eisenach JC: Adenosine reduces glutamate release in rat spinal synaptosomes. Anesthesiology 2005, 103:1060-1065.
37. Sharma M, Mohta M, Chawla R: Efficacy of intrathecal adenosine for postoperative pain relief. Eur J Anaesthesiol 2006, 23:449-453.
38. Hayashida M, Fukuda K, Fukunaga A: Clinical application of adenosine and ATP for pain control. J Anesth 2005, 19:225-235.
39. Belfrage M, Segerdahl M, Arńr S, Sollevi A: The safety and efficacy of intrathecal adenosine in patients with chronic neuropathic pain. Anesth Analg 1999, 89:136-142.
40. Karlsten R, Gordh T Jr: An A1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection. Anesth Analg 1995, 80:844-847.
41. Rane K, Segerdahl M, Goiny M, Sollevi A: Intrathecal adenosine administration: a phase 1 clinical safety study in healthy volunteers, with additional evaluation of its influence on sensory thresholds and experimental pain. Anesthesiology 1998, 89:1108- 1115; discussion 1109A.
42. Deer T, Krames ES, Hassenbusch S, et al.: Future directions for intrathecal pain management: a review and update from the Interdisciplinary Polyanalgesic Consensus Conference 2007. Neuromodulation 2008, 11:92-97.
43. Nielsen CK, Lewis RJ, Alewood D, et al.: Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain. Pain 2005, 118:112-124.
44. Szabo T, Olah Z, Iadarola MJ, Blumberg PM: Epidural resiniferatoxin induced prolonged regional analgesia to pain. Brain Res 1999, 840:92-98.
45. Clinical Trials: resiniferatoxin to treat severe pain associated with advanced cancer. Available at NCT00804154. Accessed December 2009.
46. Allen JW, Mantyh PW, Horais K, et al.: Safety evaluation of intrathecal substance P-saporin, a targeted neurotoxin, in dogs. Toxicol Sci 2006, 91:286-298.
47. Wiley RG: Substance P receptor-expressing dorsal horn neurons: lessons from the targeted cytotoxin, substance P-saporin. Pain 2008, 136:7-10.
48. Smith TJ, Staats PS, Deer T, et al.: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drugrelated toxicity, and survival. J Clin Oncol 2002, 20:4040-4049.
49. Yaksh TL, Reddy SV: Studies in the primate on the analgetic effects associated with intrathecal actions of opiates, alpha-adrenergic agonists and baclofen. Anesthesiology 1981, 54:451-467.
50. Wallace MS, Yaksh TL: Long-term intraspinal drug therapy: a review. Reg Anesth Pain Med 2000, 25:117-157.
51. Yaksh TL, Malmberg, AB: Interaction of spinal modulatory receptor systems. In Progress in Pain Research and Management, vol 1. Edited by Fields HL, Liebeskind JC. Seattle: IASP Press; 1994:151-171.
52. Yaksh TL, Rathbun M, Provencher JC: Preclinical drug safety evaluation. In Spinal Drug Delivery. Edited by Yaksh TL. Elsevier; 1999.
53. Kan J, Yang Z, Tang K, Cheng G: Pumping performance of a new piezoelectric pump for drug delivery. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2004, 21:297-301.
54. InSet Technologies, Inc.: Information on file with the company. Available at http://www.insetinc.com. Accessed December 2009.
55. Rosen S, Deer T, Rauck R, et al.: Multi-center evaluation of drug delivery accuracy with the Prometra intrathecal infusion pump. Pain Med 2009, 10:124.
56. Clinical Trials: Prometra implantable programmable pump (PUMP). Available at http://clinicaltrials.gov/ct2/show/NCT00817596 Accessed December 2009
57. Clinical Trials: Prometra's utilization in mitigating pain II (PUMP2). Available at . http://clinicaltrials.gov/ct2/show/NCT00866164. Accessed December 2009
58. Berg A, Barsa T, Deer T, et al.: Efficacy of morphine sulfate infusion via the Prometra® intrathecal infusion pump. A prospective multicenter evaluation. Presented at the 5th World Congress Institute of Pain. New York, NY; March 15, 2009.
59. Codman: Information on file with the company.Available at http://www.codman.com/DePuy/home/index.html. Accessed December 2009.
60. Smith Medical: Infusion systems. Available at http://www.smithsmedical. com/products/infusion/. Accessed December 2009.
61. US Food and Drug Administration: PMA: premarket approval. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/PMA.cfm?ID=4499. Accessed December 2009.
62. Ilias W, le Polain B, Buchser E, Demartini L; oPTiMa study group: Patient-controlled analgesia in chronic pain patients: experience with a new device designed to be used with implanted programmable pumps. Pain Pract 2008, 8:164-170.
63. Rainov NG, Buchser E: Making a case for programmable pumps over fixed rate pumps for the management of fluctuations in chronic pain and spasticity: a literature review. Neuromodulation 2002, 5:88-99.
64. Coffey RJ, Owens ML, Broste SK, et al.: Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesia 2009, 111:881-892.
65. Ghafoor VL, Epshteyn M, Carlson GH, et al.: Intrathecal drug therapy for long-term pain management. Am J Health Syst Pharm 2007, 64:2447-2461.
66. Hassenbusch S, Burchiel K, Coffey RJ, et al.: Management of intrathecal catheter-tip inflammatory masses: a consensus statement. Pain Med 2002, 3:313-323.